InvestSMART

4DMedical Limited (ASX: 4DX) - Announcements

Current share price for 4DX : $3.540 0.06 (1.67%)+

ASX company news and announcements for 4DMedical Limited (4DX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All 4DMedical Limited (4DX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than 4DMedical Limited (4DX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for 4DMedical Limited (4DX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,112 Results of EGM 1 May 2025 11:43AM $0.305 $3.520 risen by 1,054.10%
$2,112 Quarterly Activity Report and Appendix 4C for Q3 FY2025 29 Apr 2025 10:31AM $0.285 $3.520 risen by 1,135.09%
$2,112 Notification regarding unquoted securities - 4DX 24 Apr 2025 4:02PM $0.280 $3.520 risen by 1,157.14%
$2,112 Application for quotation of securities - 4DX 24 Apr 2025 3:57PM $0.285 $3.520 risen by 1,135.09%
$2,112 Revised Target Market Determination 16 Apr 2025 8:59AM $0.300 $3.520 risen by 1,073.33%
$2,112 Supplementary Prospectus 16 Apr 2025 8:53AM $0.300 $3.520 risen by 1,073.33%
$2,112 Change of registry address 15 Apr 2025 3:16PM $0.293 $3.520 risen by 1,103.42%
$2,112 4DMedical converts Integral Diagnostics pilot into contract 15 Apr 2025 8:33AM $0.255 $3.520 risen by 1,280.39%
$2,112 Notification of cessation of securities - 4DX 11 Apr 2025 2:51PM $0.250 $3.520 risen by 1,308%
$2,112 4DMedical wins industry partners and discussed in Congress 10 Apr 2025 10:38AM $0.260 $3.520 risen by 1,253.85%
$2,112 Letter to Shareholders, Notice of EGM & Proxy Form 1 Apr 2025 8:46AM $0.270 $3.520 risen by 1,203.70%
$2,112 Cost reduction program delivers $6.5m in annualised savings 26 Mar 2025 9:58AM $0.355 $3.520 risen by 891.55%
$2,112 Target Market Determination 25 Mar 2025 5:34PM $0.355 $3.520 risen by 891.55%
$2,112 Prospectus 25 Mar 2025 5:31PM $0.355 $3.520 risen by 891.55%
$2,112 Application for quotation of securities - 4DX 25 Mar 2025 10:57AM $0.365 $3.520 risen by 864.38%
$2,112 4DMedical completes oversubscribed $8.4m SPP 25 Mar 2025 9:30AM $0.360 $3.520 risen by 877.78%
$2,112 3-year contract extension secured with the Cleveland Clinic 11 Mar 2025 8:24AM $0.390 $3.520 risen by 802.56%
$2,112 Notification of cessation of securities - 4DX 3 Mar 2025 3:08PM $0.385 $3.520 risen by 814.29%
$2,112 Change of Director's Interest Notice 3 Mar 2025 2:55PM $0.385 $3.520 risen by 814.29%
$2,112 Change of Director's Interest Notice 3 Mar 2025 2:55PM $0.385 $3.520 risen by 814.29%
$2,112 Change in substantial holding 28 Feb 2025 2:34PM $0.393 $3.520 risen by 796.82%
$2,112 Change in substantial holding 28 Feb 2025 2:33PM $0.393 $3.520 risen by 796.82%
$2,112 Change in substantial holding 28 Feb 2025 2:30PM $0.393 $3.520 risen by 796.82%
$2,112 Cleansing Notice - Placement 28 Feb 2025 10:49AM $0.400 $3.520 risen by 780%
$2,112 1H FY2025 Investor Presentation 28 Feb 2025 10:46AM $0.400 $3.520 risen by 780%

201 - 225 of 596 results

Page 9 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.